Our understanding of the development and progression of atherosclerosis has increased substantially over the past decades. A significant role for the renin-angiotensin-aldosterone system (RAAS) in this process has gained appreciation in recent years. Preclinical and clinical studies have associated components of the RAAS with various cardiovascular disease conditions. Classically known for its contribution to hypertension, dysregulation of the system is now also believed to promote vascular inflammation, fibrosis, remodeling, and endothelial dysfunction, all intimately related to atherosclerosis. The reduction in cardiovascular mortality and morbidity, as seen with the use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, supports the concept that RAAS is involved in the pathogenesis of atherosclerotic disease. However, the underlying molecular mechanisms of the pathophysiology remain to be completely understood. Evidence points toward additional benefit from therapeutic approaches aiming at more complete inhibition of the system and the possible utility of renin or aldosterone in the prediction of cardiovascular outcome. This review will summarize the current knowledge from clinical studies regarding the presumptive role of renin and aldosterone in the prediction and management of patients with atherosclerosis. For this purpose, a literature search was performed, focusing on available clinical data regarding renin or aldosterone and cardiovascular outcome.
Authors: Marieke A Hillaert, Eef G Lentjes, Farzin Beygui, Hans Kemperman, Folkert W Asselbergs, Hendrik M Nathoe, Pierfrancesco Agostoni, Michiel Voskuil, Fabrice Ivanes, Brigitte Jude, Michel E Bertrand, Gerard Pasterkamp, Yolanda van der Graaf, Pieter A Doevendans, Gilles Montalescot, Eric Van Belle
Keywords: aldosterone, renin, atherosclerosis
DOI Number: 10.1016/j.ahj.2011.06.015 Publication Year: 2011
To search for other research papers by topic, keyword, author, or year, please go to our Publications page.